PH12019502792A1 - Tetrahydropyridopyrazine modulators of gpr6 - Google Patents

Tetrahydropyridopyrazine modulators of gpr6

Info

Publication number
PH12019502792A1
PH12019502792A1 PH12019502792A PH12019502792A PH12019502792A1 PH 12019502792 A1 PH12019502792 A1 PH 12019502792A1 PH 12019502792 A PH12019502792 A PH 12019502792A PH 12019502792 A PH12019502792 A PH 12019502792A PH 12019502792 A1 PH12019502792 A1 PH 12019502792A1
Authority
PH
Philippines
Prior art keywords
gpr6
tetrahydropyridopyrazine
modulators
compound
formula
Prior art date
Application number
PH12019502792A
Other languages
English (en)
Inventor
Jason W Brown
Stephen Hitchcock
Maria Hopkins
Shota Kikuchi
Holger Monenschein
Holly Reichard
Kristin Schleicher
Huikai Sun
Todd Macklin
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PH12019502792A1 publication Critical patent/PH12019502792A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12019502792A 2017-06-15 2019-12-10 Tetrahydropyridopyrazine modulators of gpr6 PH12019502792A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762520430P 2017-06-15 2017-06-15
US201762591247P 2017-11-28 2017-11-28
US201862649856P 2018-03-29 2018-03-29
US201862672261P 2018-05-16 2018-05-16
PCT/US2018/037687 WO2018232202A1 (en) 2017-06-15 2018-06-15 Tetrahydropyridopyrazine modulators of gpr6

Publications (1)

Publication Number Publication Date
PH12019502792A1 true PH12019502792A1 (en) 2020-09-14

Family

ID=64656005

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019502792A PH12019502792A1 (en) 2017-06-15 2019-12-10 Tetrahydropyridopyrazine modulators of gpr6

Country Status (25)

Country Link
US (1) US10406157B2 (enExample)
EP (1) EP3638673B9 (enExample)
JP (2) JP7460369B2 (enExample)
KR (1) KR102802861B1 (enExample)
CN (1) CN110730781B (enExample)
AU (1) AU2018285677B2 (enExample)
CA (1) CA3067032A1 (enExample)
CO (1) CO2019015086A2 (enExample)
DK (1) DK3638673T3 (enExample)
ES (1) ES2988680T3 (enExample)
FI (1) FI3638673T3 (enExample)
HR (1) HRP20241231T1 (enExample)
HU (1) HUE068346T2 (enExample)
IL (1) IL271332B2 (enExample)
JO (1) JOP20180057A1 (enExample)
LT (1) LT3638673T (enExample)
MX (1) MX2019014940A (enExample)
PH (1) PH12019502792A1 (enExample)
PL (1) PL3638673T3 (enExample)
PT (1) PT3638673T (enExample)
RS (1) RS66018B1 (enExample)
SG (1) SG11201912149WA (enExample)
SI (1) SI3638673T1 (enExample)
TW (1) TWI775874B (enExample)
WO (1) WO2018232202A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026067262A1 (zh) * 2024-09-26 2026-04-02 四川科伦药物研究院有限公司 并环化合物、包含其的药物组合物及其用途和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7229557B2 (en) 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
WO2011005636A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Tetrahydronapthyridine orexin receptor antagonists
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
UA117779C2 (uk) * 2014-02-14 2018-09-25 Такеда Фармасьютікал Компані Лімітед Піразини як модулятори gpr6
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Gpr6のピリドピラジンモジュレーター

Also Published As

Publication number Publication date
EP3638673B9 (en) 2024-11-20
CN110730781A (zh) 2020-01-24
PT3638673T (pt) 2024-10-07
IL271332B2 (en) 2023-02-01
CN110730781B (zh) 2023-05-05
AU2018285677A1 (en) 2019-12-19
FI3638673T3 (fi) 2024-09-13
KR20200014796A (ko) 2020-02-11
AU2018285677B2 (en) 2022-07-14
TWI775874B (zh) 2022-09-01
HUE068346T2 (hu) 2024-12-28
JP2020523287A (ja) 2020-08-06
JP7497400B2 (ja) 2024-06-10
PL3638673T3 (pl) 2024-11-18
EP3638673B1 (en) 2024-07-17
SG11201912149WA (en) 2020-01-30
US20180360831A1 (en) 2018-12-20
US10406157B2 (en) 2019-09-10
KR102802861B1 (ko) 2025-04-30
LT3638673T (lt) 2024-09-10
WO2018232202A1 (en) 2018-12-20
CA3067032A1 (en) 2018-12-20
EP3638673A4 (en) 2021-03-24
RU2019144408A (ru) 2021-07-15
IL271332B (en) 2022-10-01
TW201906844A (zh) 2019-02-16
IL271332A (en) 2020-01-30
HRP20241231T1 (hr) 2024-12-20
JP7460369B2 (ja) 2024-04-02
MX2019014940A (es) 2020-02-19
SI3638673T1 (sl) 2025-01-31
DK3638673T3 (da) 2024-09-16
NZ759708A (en) 2024-04-26
EP3638673A1 (en) 2020-04-22
JP2022188199A (ja) 2022-12-20
ES2988680T3 (es) 2024-11-21
RS66018B1 (sr) 2024-11-29
CO2019015086A2 (es) 2020-04-13
RU2019144408A3 (enExample) 2021-09-07
BR112019026430A2 (pt) 2020-07-14
JOP20180057A1 (ar) 2019-01-30

Similar Documents

Publication Publication Date Title
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
AU2018253590A1 (en) Imidazopyridazine compounds
EP4609866A3 (en) Oxysterols and methods of use thereof
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
EP4316591A3 (en) Oxysterols and methods of use thereof
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MY206763A (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
WO2017177004A8 (en) Tertiary amides and method of use
SG10201907291QA (en) Monomethylfumarate prodrug compositions
PH12017500595A1 (en) Aldosterone synthase inhibitors
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
PH12019500822B1 (en) Crystalline forms of eravacycline
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2017214423A8 (en) Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
WO2015138276A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
ZA202103209B (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
MY189372A (en) Indole derivatives
PH12017501134A1 (en) Fumagillol derivatives
JOP20180057A1 (ar) مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6